CA3154302A1 - Stable, concentrated radiopharmaceutical composition - Google Patents
Stable, concentrated radiopharmaceutical composition Download PDFInfo
- Publication number
- CA3154302A1 CA3154302A1 CA3154302A CA3154302A CA3154302A1 CA 3154302 A1 CA3154302 A1 CA 3154302A1 CA 3154302 A CA3154302 A CA 3154302A CA 3154302 A CA3154302 A CA 3154302A CA 3154302 A1 CA3154302 A1 CA 3154302A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- salts
- acid
- composition according
- ascorbic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
- A61K51/121—Solutions, i.e. homogeneous liquid formulation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19197607 | 2019-09-16 | ||
| EP19197607.5 | 2019-09-16 | ||
| PCT/EP2020/075767 WO2021052960A1 (en) | 2019-09-16 | 2020-09-15 | Stable, concentrated radiopharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3154302A1 true CA3154302A1 (en) | 2021-03-25 |
Family
ID=67981980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3154302A Pending CA3154302A1 (en) | 2019-09-16 | 2020-09-15 | Stable, concentrated radiopharmaceutical composition |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220401593A1 (https=) |
| EP (1) | EP4031193A1 (https=) |
| JP (2) | JP7762648B2 (https=) |
| KR (1) | KR20220063218A (https=) |
| CN (1) | CN114728088A (https=) |
| AR (1) | AR119974A1 (https=) |
| AU (1) | AU2020349002B2 (https=) |
| CA (1) | CA3154302A1 (https=) |
| IL (1) | IL291315A (https=) |
| TW (1) | TW202123976A (https=) |
| WO (1) | WO2021052960A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4442285A1 (en) * | 2021-11-30 | 2024-10-09 | Nihon Medi-Physics Co., Ltd. | Stabilized radiopharmaceutical composition |
| CN114404618A (zh) * | 2022-03-28 | 2022-04-29 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其用途 |
| CN114404619A (zh) * | 2022-03-28 | 2022-04-29 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其制备方法和用途 |
| CN116920129A (zh) * | 2022-04-02 | 2023-10-24 | 北京先通国际医药科技股份有限公司 | 放射性药物水溶液及其制备方法和用途 |
| JP2026505341A (ja) | 2023-02-08 | 2026-02-13 | ノバルティス アーゲー | 神経膠芽腫を治療するための方法 |
| IL322257A (en) | 2023-02-23 | 2025-09-01 | Novartis Ag | Methods of treating breast cancer |
| CN121793988A (zh) | 2023-09-13 | 2026-04-03 | 东丽株式会社 | 癌的治疗、预防和/或诊断用药物组合物 |
| TW202527951A (zh) | 2023-12-15 | 2025-07-16 | 瑞士商諾華公司 | 用於治療乳腺癌的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5139678B2 (ja) * | 2003-07-24 | 2013-02-06 | ブラッコ・イメージング・ソシエタ・ペル・アチオニ | 安定な放射性医薬品組成物およびその製法 |
| WO2008009444A1 (en) | 2006-07-19 | 2008-01-24 | Van Dulmen, Adrianus, A. | Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide |
| ES2745635T3 (es) | 2012-09-25 | 2020-03-03 | Advanced Accelerator Applications Usa Inc | Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR |
-
2020
- 2020-09-15 KR KR1020227012069A patent/KR20220063218A/ko active Pending
- 2020-09-15 EP EP20768373.1A patent/EP4031193A1/en active Pending
- 2020-09-15 US US17/753,762 patent/US20220401593A1/en active Pending
- 2020-09-15 TW TW109131644A patent/TW202123976A/zh unknown
- 2020-09-15 AR ARP200102561A patent/AR119974A1/es unknown
- 2020-09-15 CA CA3154302A patent/CA3154302A1/en active Pending
- 2020-09-15 JP JP2022516404A patent/JP7762648B2/ja active Active
- 2020-09-15 AU AU2020349002A patent/AU2020349002B2/en active Active
- 2020-09-15 CN CN202080079709.9A patent/CN114728088A/zh active Pending
- 2020-09-15 WO PCT/EP2020/075767 patent/WO2021052960A1/en not_active Ceased
-
2022
- 2022-03-13 IL IL291315A patent/IL291315A/en unknown
-
2025
- 2025-06-11 US US19/234,864 patent/US20250332301A1/en active Pending
- 2025-10-20 JP JP2025176508A patent/JP2026031934A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AR119974A1 (es) | 2022-01-26 |
| EP4031193A1 (en) | 2022-07-27 |
| WO2021052960A1 (en) | 2021-03-25 |
| US20220401593A1 (en) | 2022-12-22 |
| JP2022548875A (ja) | 2022-11-22 |
| IL291315A (en) | 2022-05-01 |
| CN114728088A (zh) | 2022-07-08 |
| KR20220063218A (ko) | 2022-05-17 |
| TW202123976A (zh) | 2021-07-01 |
| US20250332301A1 (en) | 2025-10-30 |
| JP2026031934A (ja) | 2026-02-25 |
| AU2020349002A1 (en) | 2022-04-28 |
| JP7762648B2 (ja) | 2025-10-30 |
| AU2020349002B2 (en) | 2024-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2020349002B2 (en) | Stable, concentrated radiopharmaceutical composition | |
| TWI878344B (zh) | 放射性標記grpr拮抗劑之方法及其套組 | |
| JP2023546525A (ja) | 前立腺特異的膜抗原を標的とする化合物及びその調製方法と応用 | |
| JP7097436B2 (ja) | エバンスブルー誘導体の化学的コンジュゲートおよびそれらの放射線治療剤および造影剤としての使用 | |
| JP2024038107A (ja) | 放射性核種錯体を調製するための方法およびキット | |
| JP2025506001A (ja) | ２２５－アクチニウム標識錯体及びビスマス封鎖剤を含む医薬組成物 | |
| AU2019289884B2 (en) | Composition containing a somatostatin analogue for radiopharmaceutical use | |
| CA3155462A1 (en) | Radiolabelled grpr-antagonist for use as theragnostic | |
| RU2839656C1 (ru) | Стабильная концентрированная радиофармацевтическая композиция | |
| US20250313579A1 (en) | Ligand compounds comprising a chelating group as a bridging group | |
| CN103153349A (zh) | 用于治疗人类肝癌的基于铼-188的组合物和制备这种组合物的方法 | |
| RU2855011C1 (ru) | Способы мечения радиоактивными изотопами антагонистов grpr и наборы на для их осуществления | |
| WO2026012457A1 (zh) | 骨靶向放射性药物及其用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240823 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240823 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240823 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20240906 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241118 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241202 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250414 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250819 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250819 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260212 |